The Mayo Clinic Hospital — Rochester is a 2,059-bed hospital located in Rochester, Minnesota. It comprises the Saint Marys Campus, and Mayo Eugenio Litta Children's Hospital, forming an integral part of the Mayo Clinic academic medical center. Mayo Clinic Hospital — Rochester is ranked first on the 2019-20 U.S. News & World Report Best Hospitals Honor Roll and is ranked #1 in more specialties than any other hospital in the United States.
Venetoclax (Ven) plus hypomethylating agents (HMA) is standard frontline therapy for newly diagnosed AML (ND-AML) patients unfit for intensive chemotherapy and is also considered in younger, fit patients. However, consolidation with allogeneic stem cell transplant (ASCT) is often required to secure durable remission. The current study examines posttransplant outcomes in patients with ND-AML treated with frontline Ven-HMA who subsequently underwent ASCT. A total of 111 ND-AML patients (58% male, 60% secondary/therapy-related, median age 70 years [range, 37-80]) received a median of 3 cycles of Ven-HMA. Mutations at the time of diagnosis included RUNX1 (18%), SRSF2 (17%), TP53 (16%), ASXL1, IDH2, K/NRAS, TET2 (14% each), STAG2 (11%), DNMT3A (8%). All patients were in CR/CRi at the time of transplant including 88% after Ven-HMA. Measurable residual disease (MRD) by flow cytometry was detectable in 18/76 (24%) patients. Donors were mostly HLA-matched unrelated (75%); 51% receiving fludarabine/melphalan conditioning and 67% posttransplant cyclophosphamide. At a median follow-up of 15 months, 42 (38%) of patients have died and 18 (16%) experienced posttransplant relapse. Median posttransplant survival was not reached (NR), with 1-, 2-, 3-year survival rates of 69%/60%/57%, respectively. On multivariate analysis, age ≥ 65 years, STAG2 mutation (STAG2MUT), and DNMT3AMUT were associated with superior posttransplant survival. Patients were stratified into low- (0-1 point), intermediate- (2 points), and high-risk (3 points); age < 65 years, STAG2 wild type, and DNMT3A wild type, with 3-year survival rates of 89%, 59%, and 19%, respectively (p < 0.01). Taken together, age, STAG2MUT and DNMT3AMUT stratified posttransplant survival in Ven-HMA treated patients with ND-AML.
The recent inclusion of the Merlin clinicopathologic-gene expression profile (CP-GEP) assay in the National Comprehensive Cancer Network (NCCN) Melanoma Guidelines represents an important milestone in the clinical integration of molecular testing for cutaneous melanoma. Unlike earlier melanoma gene expression profile (GEP) assays, which focused primarily on prognostic risk stratification, CP-GEP was specifically developed to predict sentinel lymph node (SLN) metastasis risk by identifying early metastatic competence within primary melanomas, with additional prognostic utility. This review discusses the biological evidence supporting CP-GEP and examines how unbiased transcriptomic discovery converged with established insights from cancer cell biology, integrin signaling, focal adhesions, and extracellular matrix (ECM) remodeling to shape its conceptual framework. We further discuss how CP-GEP captures a transformation-associated biological state centered on an integrin- and TGF-β-dependent signaling axis (ITGB3, TGFBR1) that promotes pericellular proteolysis and ECM remodeling (PLAT, SERPINE2, LOXL4), inflammatory and angiogenic signaling (CXCL8, GDF15), and melanocytic lineage identity (MLANA). Collectively, these genes identify a dissemination-competent phenotype that is detectable within primary tumors before clinically apparent metastasis. Overall, the biological framework supporting CP-GEP reinforces the concept that altered adhesion signaling and ECM remodeling are central drivers of early melanoma metastasis and represent clinically actionable biomarkers for individualized melanoma management.
Part I of our three-part series outlines the essential technical and operational components required for successful digital pathology implementation including hardware, software, and IT infrastructure. It reviews the rationale for digitization, highlighting improvements in workflow efficiency, diagnostic collaboration, and preparedness for computational applications. Key components of Whole Slide Imaging (WSI) systems are discussed, including practical considerations for scanner selection, scanning modalities, and performance trade-offs relevant to dermatopathology. The article also examines image compression strategies and pyramid image representation, with attention to balancing image quality and storage efficiency. Finally, we review DICOM standards and storage infrastructure options, including cloud, on-premises, and hybrid models, and associated network bandwidth requirements.
BACKGROUND/OBJECTIVES:Bacterial infections are major precipitants of decompensation and death in cirrhosis. Multidrug-resistant (MDR) bacteria are increasingly recognized in this population, but their burden across infection sites and healthcare settings remains uncertain. We aimed to estimate the prevalence and distribution of MDR bacterial infections among hospitalized patients with cirrhosis and culture-proven infections. METHODS:PubMed, Embase, and Scopus were searched through November 2025 for observational studies reporting patient-level MDR prevalence among hospitalized patients with cirrhosis and culture-positive infections. A proportional meta-analysis was conducted using 95% confidence intervals (CI), and heterogeneity was assessed with the I² statistic. Stratified analyses were performed based on epidemiological and clinical factors. RESULTS:Twenty-nine studies including 13,361 patients were analyzed. Across heterogeneous hospitalized cirrhosis cohorts, the prevalence of patients with MDR bacterial infections was 36.73% (95% CI: 32.23-41.35%; I² = 92.9%). Asia had the highest estimate, at 41.95% (95% CI: 34.36-49.74%; I² = 90.6%). Europe had a prevalence of 31.75% (95% CI: 27.37-36.29%; I² = 66.3%), Latin America of 31.10% (95% CI: 23.77-38.94%; I² = 74.9%), and North America of 23.33% (95% CI: 13.07-35.50%; I² = 82.9%). Data from Oceania and Africa were limited. Acinetobacter spp. showed the strongest association with MDR, at 85.06% (95% CI: 54.39-99.73%; I² = 77.2%), whereas Escherichia coli was the most common MDR bacteria, at 42.39% (95% CI: 31.57-53.59%; I² = 90.7%). CONCLUSION:MDR bacteria are common among hospitalized patients with cirrhosis and culture-proven infections. Gram-negative organisms predominate, with E. coli accounting for the largest absolute MDR burden, while Acinetobacter spp. showed the highest pathogen-specific probability of MDR.